

PARMAX PHARMA LIMITED

Financial statement for the quarter ended 31.03.2015

1	Net Sale / Income from Operation			
	Commission received	-		
	Other income	-		
			-	
	(A)			
2	Other Income	-	600,000.00	
3	Total Expenditure			
	(a) Increase / Decrease in stock		-	
	(b) Purchase of Shares & Securities		-	
			-	
	(c) Staff Cost			
	Salary & Directors Remuneration	-		
	Staff Welfare	-	-	
	(d) Other Expenditure		33,433.00	
4	(B)		33,433.00	
	Profit (+ or -) before Dep.(A-B)			566,567.00
	Depreciation			-
	Profit (+ or -) after Dep.			566,567.00

Unaudited Financial Results (Provisional) for the Quarter Ended 31.03.2015

Sr. No	Particulars	3 months ended 31.03.2015	Corresponding 3 months ended 31.03.2014	Six month ended 31.03.2015	Corresponding Six month ended 31.03.2014	Year Ended 31.03.2014
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	a Net Sales/Income from Operations	-	-	-	-	-
	b Other operating Income	600,000.00	600,000.00	600,000.00	600,000.00	600,292.00
	Total Income	600,000.00	600,000.00	600,000.00	600,000.00	600,292.00
2	Expenditure					
	a :(Increase)/Decrease in Stock-in-Trade	-	-	-	-	-
	b : Consumption of Raw Material	-	-	-	-	-
	c : Purchase of traded goods	-	-	-	-	-
	d : Employees Cost	-	-	-	-	-
	e : Depreciation	-	-	-	-	-
	f : Other Expenditure	33,433.00	70,832.00	117,692.00	164,710.00	200,204.00
	g Total	33,433.00	70,832.00	117,692.00	164,710.00	200,204.00
3	Profit from Operations before other Income, Interest and Exceptional Items (1-2)	566,567.00	529,168.00	482,308.00	435,290.00	400,088.00
4	Other Income	-	-	-	-	-
5	Profit before Interest and Exceptional Items (3+4)	566,567.00	529,168.00	482,308.00	435,290.00	400,088.00
6	Interest	-	-	-	-	-
7	Profit after interest but before exceptional items (5-6)	566,567.00	529,168.00	482,308.00	435,290.00	400,088.00
8	Exceptional Items	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7+8)	566,567.00	529,168.00	482,308.00	435,290.00	400,088.00
10	Tax Expenses	-	-	-	-	-
11	Net Profit from Ordinary Activities after Tax (9-10)	566,567.00	529,168.00	482,308.00	435,290.00	400,088.00
12	Extraordinary item	-	-	-	-	-
13	Net Profit for the period (11-12)	566,567.00	529,168.00	482,308.00	435,290.00	400,088.00
14	Paid-up Equity Share Capital-[Face Value. Rs 10]	39,020,500.00	39,020,500.00	39,020,500.00	39,020,500.00	39,020,500.00
15	Reserve excluding revaluation reserve	-	-	-	-	941,177.00
16	Basic & Diluted EPS	-	-	-	-	-
17	Public Shareholding					
	Number of Shares					
	% of Shareholding					
18	Promoters and promoter group Shareholding					
	a Pledge / Encumbered					
	Number of Shares	NIL	NIL	NIL	NIL	NIL
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	Percentage of Shares (as a % of the total Share Capital of the Company)	NIL	NIL	NIL	NIL	NIL
	b Non encumbered					
	Number of Shares					
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)					
	Percentage of Shares (as a % of the total Share Capital of the Company)					

Notes :

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on
- There were no investors complaints during the quarter ended 31st Mar 2015
- Previous years figures has been regroup / rearranged wherever necessary.

PARMAX PHARMA LIMITED

Alkesh M. Gopani
Director



Place Hadamtala (Rajkot)

Date:

Clause 41 of the Listing Agreement For companies (Other than Banks)

	Stadalone / Consolidated Statement of Assets and Liabilities Particulars	As at (31-03-15)	As at (31/03/14)
A	EQUITY AND LIABILITIES		
1	Shareholder's funds		
	(a) Share capital	40295500	39020500
	(b) Reserves and surplus	1,165,894	941,177
	© Money received against share warrants	0	0
	Sub- total - Shareholder's funds	41461394	39961677
	Share application money pending allotment	0	0
2			
3	Minority interest*	0	0
4	Non-current liabilities		
	(a) Long-term borrowings	7899176	9174177
	(b) Deferred tax liabilities (net)	0	0
	© Other long-term liabilities	0	0
	(d) Long-term provisions	0	0
	Sub-total-Non-current liabilities	7899176	9174177
5	Current liabilities		
	(a) Short-term borrowings	0	0
	(b) Trade payables	66232	698698
	(c) Other current liabilities	0	1760
	(d) Short-term provisions	315000	155000
	Sub-total- Current liabilities	381232	855458
	TOTAL - EQUITY AND LIABILITIES	49741802	49991312
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	25331120	25331120
	(b) Goodwill on consolidation*	0	0
	(c) Non-current investments	6000	6000
	(d) Deferred tax assets (net)	0	0
	(e) Long-term loans and advances	734400	734400
	(f) Other non-current assets	8524466	8524466
	Sub-total-Non-current assets	34595986	34595986
2	Current assets		
	(a) Current investments	0	0
	(b) Inventories	0	0
	© Trade receivables	824150	630000
	(d) Cash and cash equivalents	2149699	2739207
	(e) Short-term loans and advances	12171967	12026119
	(f) Other current assets	0	0
	Sub-total-Current assets	15145816	15395326
	TOTAL - ASSETS	49741802	49991312

BHARAT A. SHAH

B.Com. F.C.A. (DISA)

B. A. SHAH ASSOCIATES

Chartered Accountants

209 Sapphire, 2nd Floor, 21/25 – B, New Jagnath Plot, Rajkot. – 360 001. Ph.: 0281 - 2468261

Auditor's Limited Review Report

On Unaudited Financial Results

To

**The Board of Directors,
Parmax Pharma Limited**

We have reviewed the accompanying statement of unaudited financial results of **PARMAX PHARMA LIMITED** for the quarter ended on **31st March 2015**. This statement is the responsibility of the Company's Management.

A review of the interim financial information consist principally of applying analytical procedures for the financial data and making enquiries of persons responsible for financial and accounting matters. It is substantially less in scope than audit conducted in accordance with the generally accepted auditing standards, The objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly we do not express such an opinion. Further our review was mainly in regards to the figures of quarter ended 31st March 2015.

During our review we have noticed that:

There are small differences between amounts as per published results and corresponding figured as per the accounts (which are however within the allowed limit of 10% or Rs. 10 lacs, whichever is higher)

Except this nothing has come to our notice that causes us to believe that the accompanying statements of unaudited financial results have not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed or that it contain any material misstatement.

For B A SHAH ASSOCIATES

Chartered Accountants

FRN.: 109493W

Bharat A Shah

BHARAT SHAH

PROPRIETOR

M. NO.034222



Date: 30.04.2015

Place: Rajkot